Skip to main content
SP5007,662.23-0.16%DOW53,398.87+0.23%NASDAQ26,074.75-0.40%BTC$79,148.00+2.41%ETH$2,481.33+1.38%GOLD$4,703.90+0.50%OIL$85.11-2.24%
Smart Investors Daily
Sign InSign Up Free
TC

OTC · TCON

TRACON Pharmaceuticals, Inc.

Healthcare · Biotechnology

$0.03

Up+$0.00 (+0.00%)

Updated Aug 24, 2026, 4:16 PM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
109.73K
P/E ratio
-0.01
Dividend yield
0.00%
52-week range
— – —
Volume
15.05K
Avg. volume
14.43K

Price performance

TCON price history

1M range · 0 trading sessions · Daily adjusted prices

TCON does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest TCON news

The latest Smart Investors Daily articles mentioning TCON.

Stock researchCompany · Overview

TCON research

Overview

Company profile and research snapshot.

Company profile

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
—
Implied upside
—
Analysts
7
TCON recent ratings
DateFirmRatingTarget
Jul 1, 2024HC Wainwright & Co.Neutral—
Apr 3, 2024HC Wainwright & Co.Buy—
Mar 6, 2024HC Wainwright & Co.Buy—
Nov 20, 2023HC Wainwright & Co.Buy—
Aug 21, 2023JonesTradingHold—
Open full forecast

News briefing

No generated briefing is available yet.

GlobeNewswire Inc. · May 14, 2024

TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the first quarter ended March 31, 2024. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time.

GlobeNewswire Inc. · May 7, 2024

TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024

SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its first quarter 2024 financial and operating results after the close of U.S. financial markets on Tuesday, May 14, 2024. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.

Benzinga · Apr 15, 2024

Why Medical Properties Trust Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

Shares of Medical Properties Trust, Inc. (NYSE: MPW) rose sharply in today’s pre-market trading after the company announced that it sold its majority interest in Utah Hospitals. Medical Properties Trust shares jumped 13.1% to $4.51 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) shares rose 51% to $3.17 in pre-market trading after dipping 9% on Friday. Allarity Therapeutics filed prospectus supplement to increase offering price of common stock that may be offered from $2.35 million to $3.2 million. Longeveron Inc. (NASDAQ: LGVN) gained 38.4% to $2.34 in pre-market trading after falling 16% on Friday. Longeveron, last week, announced closing of $5.2 million public offering. SuperCom Ltd. (NASDAQ: SPCB) shares gained 34.8% to $0.3722 in pre-market trading after jumping around 18% on Friday. HUB Cyber Security Ltd. (NASDAQ: HUBC) climbed 29.2% to $1.68 in pre-market trading ...

GlobeNewswire Inc. · Apr 8, 2024

TRACON Pharmaceuticals Announces Reverse Stock Split

SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent Product Development Platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced that, following stockholder approval at the special meeting of stockholders held on September 6, 2023 of a proposal authorizing the board of directors of the Company (the Board) to amend the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s outstanding common stock at a ratio in the range of one-for-five to one-for-twenty, the Company’s Board today approved a reverse stock split of the Company’s common stock at a ratio of one-for-twenty.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By